« Return to News | Awards & Advancement

Blueprint Medicines names Christoph Lengauer chief scientific officer

Friday, February 10, 2012 11:44 AM

Blueprint Medicines, a Cambridge, Mass.-based developer of personalized cancer therapies, has appointed Christoph Lengauer, Ph.D., chief scientific officer.

Lengauer most recently was vice president and global head of oncology drug discovery and preclinical development at Sanofi. Previously, he was executive director and senior unit head, oncology discovery at the Novartis Institutes for Biomedical Research, and an associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.

Lengauer has a proven track record in cancer drug discovery, including contributing to 17 development candidates, 11 drugs/programs that reached first-in-human clinical trials and two registered drugs. He is lead or senior author of several scientific articles published in journals such as Cell, Nature and Science.

"Christoph has been at the forefront of the development of several novel and effective cancer drugs that have had a significant impact on patients' lives and brings a powerful understanding of cancer drug development to Blueprint," said Nicholas Lydon, Ph.D., scientific co-founder of Blueprint Medicines. "He is uniquely suited to lead our cancer therapeutics development strategy, and we believe his appointment is a true validation of the potential of Blueprint Medicines' platform and our ability to leverage emerging molecular insights to develop genomically-driven, highly selective therapies."

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.